Clinical isolates of Panton–Valentine leucocidin- and γ-haemolysin-producing Staphylococcus aureus: prevalence and association with clinical infections

Mesrati, I.; Saïdani, Mabrouka; Ennigrou, S.; Zouari, B.; Redjeb, S. Ben

doi:10.1016/j.jhin.2010.03.015

Cited by 18 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The demographic data are concordant with those of previous studies: PVL-SA tends to be communityacquired [20,21], affect healthy young individuals [8,9,12,19] with males predominating [10]. There was no strong preponderance of either MSSA or MRSA, supporting most of the available evidence [11,12,22,23].…”

Section: Demographics and Infection Characteristicssupporting

confidence: 90%

Panton-Valentine Leukocidin associated Staphylococcus aureus infections in London, England: Clinical and socio-demographic characterisation, management, burden of disease and associated costs

Edelstein

Kearns²,

Cordery

2011

Journal of Infection and Public Health

View full text Add to dashboard Cite

Routine notification of Staphylococcus aureus producing the Panton-Valentine Leucocidin toxin (PVL-SA) to the North East & Central London Health Protection Unit, a communicable disease control unit covering a population of 2.8 million, identified 115 cases in 2009-2010, including 99 skin and soft tissue infections (SSTIs), 15 severe infections and one asymptomatic colonisation. Most cases occurred in children and young adults, unequally distributed geographically and socio-economically. The majority of infections were community acquired and 60% were caused by methicillin resistant strains. Overall, 27% of cases had previous SSTIs, and 32% had contacts with SSTIs suggestive of PVL-SA albeit these were not confirmed microbiologically. This suggests that characteristics of PVL-SA infection in cases and their families are not recognised as such leading to delay in diagnosis and low case ascertainment. A lack of governance around effective case management may also be contributing to the burden of disease. Further studies are recommended to evaluate key aspects of PVL-SA management including the effectiveness of decolonisation in the elimination of carriage and prevention of local spread.

show abstract

Section: Demographics and Infection Characteristicssupporting

confidence: 90%

Panton-Valentine Leukocidin associated Staphylococcus aureus infections in London, England: Clinical and socio-demographic characterisation, management, burden of disease and associated costs

Edelstein

Kearns²,

Cordery

2011

Journal of Infection and Public Health

View full text Add to dashboard Cite

show abstract

“…This includes both subunits of LukS-LukF (Panton-Valentine leukocidin), two proteins with ϳ50% homology to LukS and LukF (SAOHUSC_02241 and SAOHUSC_02243, respectively) (16,70), and the D subunit of the LukE-LukD leukotoxin.…”

Section: Discussionmentioning

confidence: 99%

Type I Signal Peptidase and Protein Secretion in Staphylococcus aureus

Schallenberger¹,

Niessen²,

Shao³

et al. 2012

Journal of Bacteriology

View full text Add to dashboard Cite

“…Similar work in the United States (280) and France (281) established a correlation between the presence of pvl and CA-MRSA infections. In a meta-analysis of several studies (282)(283)(284)(285), the presence of pvl was clearly associated with abscesses and furuncles, with an odds ratio of 10.5 (95% CI, 7.4 to 14.9) (286). However, the quantity of PVL produced in CA-MRSA infections has not been found to correlate with the severity of infection; for example, some high-PVL-producing strains were found in patients with uncomplicated abscesses, whereas patients with necrotizing fasciitis carried S. aureus strains with lower levels of PVL production (287).…”

Section: Pathophysiologymentioning

confidence: 99%

Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

et al. 2015

View full text Add to dashboard Cite

SUMMARY Staphylococcus aureus is a major human pathogen that causes a wide range of clinical infections. It is a leading cause of bacteremia and infective endocarditis as well as osteoarticular, skin and soft tissue, pleuropulmonary, and device-related infections. This review comprehensively covers the epidemiology, pathophysiology, clinical manifestations, and management of each of these clinical entities. The past 2 decades have witnessed two clear shifts in the epidemiology of S. aureus infections: first, a growing number of health care-associated infections, particularly seen in infective endocarditis and prosthetic device infections, and second, an epidemic of community-associated skin and soft tissue infections driven by strains with certain virulence factors and resistance to β-lactam antibiotics. In reviewing the literature to support management strategies for these clinical manifestations, we also highlight the paucity of high-quality evidence for many key clinical questions.

show abstract

Clinical isolates of Panton–Valentine leucocidin- and γ-haemolysin-producing Staphylococcus aureus: prevalence and association with clinical infections

Cited by 18 publications

References 30 publications

Panton-Valentine Leukocidin associated Staphylococcus aureus infections in London, England: Clinical and socio-demographic characterisation, management, burden of disease and associated costs

Panton-Valentine Leukocidin associated Staphylococcus aureus infections in London, England: Clinical and socio-demographic characterisation, management, burden of disease and associated costs

Type I Signal Peptidase and Protein Secretion in Staphylococcus aureus

Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management

Contact Info

Product

Resources

About